Program areas at RUNX1 Research Program
2023 Independent grants include the continued support of two researchers at University of Pennsylvania: Dr. Nancy Speck ($175,000) in the optimization of RUNX1-FPD CHIP mouse models, and Dr. Ximena Jordan-Bruno, Biobanking Lead (60,000); and ongoing research with Dr. Morty Pontz at Childrens Hospital of Philadelphia CHOP ($46,875)
Sponsored Research. 2023 co-funding partnership with Alexs Lemonade Stand Foundation (ALSF) continued, $195,000 supported a wide array of ground breaking research projects spanning basic science honing in on gene regulatory networks affected by RUNX1 mutations, classification of RUNX1 variants via novel saturation mutagenesis methods, modeling clonal evolution driven by common secondary somatic mutations, development of clinical consensus guidelines for RUNX1-FPD and defining the role of NLRP3 inflammasome in RUNX1 deficiency.
Sponsored Research. 2023 co-funding partnership with the National Institutes of Health, National Institute of Allergy and Infectious Disease (NIAID) and National Cancer Institute (NCI), this grant mechanism supports 2 projects with scientific investigators Dr. Zon and Dr. Cantor both at Boston Childrens Hospital and their collaborators at NIAID and NCI, respectively. The two projects are entitled, Rescue of RUNX1 deficiency phenotypes in RUNX1-FPD patients treated with imatini and Defining clonal and metabolic alterations in the evolution of RUNX1-FPD.
Sponsored Research. 2022 Focused Impact Research (FIRE) grant program. Continued co-funding partnership with EP Evans Foundation supported two projects (Dr. Bick and Dr. Agarwal) aimed at determining the role of inflammation in the initiation and progression of hematologic malignancies driven by germline RUNX1 mutations.
Sponsored Research. 2022 Mark Foundation Cancer Research (MFCR) Seeking Transformational Research Venture (STRIVE) - Continued Grant partnership. Sponsoring Institutes include research by Dr. Lucio Castilla, University of Massachusetts Medical School.